Compare LXEO & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LXEO | EMBC |
|---|---|---|
| Founded | 2017 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.3M | 755.0M |
| IPO Year | 2023 | N/A |
| Metric | LXEO | EMBC |
|---|---|---|
| Price | $7.65 | $12.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 2 |
| Target Price | ★ $18.60 | $18.50 |
| AVG Volume (30 Days) | ★ 1.3M | 447.3K |
| Earning Date | 11-05-2025 | 02-05-2026 |
| Dividend Yield | N/A | ★ 4.97% |
| EPS Growth | N/A | ★ 20.90 |
| EPS | N/A | ★ 1.62 |
| Revenue | N/A | ★ $1,080,400,000.00 |
| Revenue This Year | N/A | $2.00 |
| Revenue Next Year | N/A | $0.27 |
| P/E Ratio | ★ N/A | $7.46 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.45 | $9.20 |
| 52 Week High | $10.99 | $19.67 |
| Indicator | LXEO | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 39.22 | 45.21 |
| Support Level | $7.02 | $12.01 |
| Resistance Level | $10.75 | $13.03 |
| Average True Range (ATR) | 0.84 | 0.45 |
| MACD | -0.24 | 0.01 |
| Stochastic Oscillator | 18.70 | 46.06 |
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.